Stavudine induced macrocytosis.

Ahmad, Saed Aftab; Sukthankar, A

doi:10.1136/sti.73.5.421

Cited by 6 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, macrocytosis was the only measure significantly associated with drug adherence. Measure of MCV as a marker of zidovudine or sta-vudine consumption already has been reported elsewhere [29][30][31][32]. It constitutes an objective measure of long-term adherence that is simple and cost-effective [33].…”

Section: Discussionmentioning

confidence: 99%

Value of Patient Self‐Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response

Duong

Piroth

Peytavin³

et al. 2001

CLIN INFECT DIS

View full text Add to dashboard Cite

Three methods of adherence to antiretroviral therapy were evaluated for 149 patients infected with human immunodeficiency virus (HIV): plasma level of protease inhibitors (PIs), patient self-report, and routine biological parameters associated with the use of some antiretroviral drugs. Adherence to therapy was estimated from a score calculated from answers to a self-administered questionnaire and on the basis of measurement of relevant plasma and blood levels. Of the 149 patients, 112 had a virologic response, and 122 had adequate trough PI levels. Plasma PI levels and virologic outcome were significantly correlated (P<.0001). The adherence score was significantly correlated with virologic response (P<.001). Macrocytosis was significantly associated with virologic response in the patients treated with zidovudine or stavudine (P=.006). PI level was the higher significant predictor of virologic response (P=.0003). Self-reported adherence (P=.01) and macrocytosis (P=.05) were also independently associated with antiretroviral efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Value of Patient Self‐Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response

Duong

Piroth

Peytavin³

et al. 2001

CLIN INFECT DIS

View full text Add to dashboard Cite

show abstract

“…Although these factors are not a contraindication for prescribing stavudine, close monitoring is essential to prevent symptomatic progression. Stavudine has little hematologic toxicity [57,65]. However, macrocytosis has been observed in 68% of patients in phase I and II trials with changes in MCV typically less than those observed in zidovudine treated patients [57].…”

Section: Nucleoside Reverse Transcriptase Inhibitors (Nrtis)mentioning

confidence: 99%

Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Max¹,

Sherer²

2000

Clinical Infectious Diseases

181

142

View full text Add to dashboard Cite

A commonly cited cause of poor adherence to highly active antiretroviral therapy (HAART) is adverse drug reactions. Short-term adverse effects are potential threats to successful introduction and maintenance of HAART. The long-term toxicities of HAART are still emerging and being defined, as evidenced by the recently described metabolic disorders (i.e., the syndrome of maldistribution, hyperlipemia, glucose intolerance and insulin resistance). With 14 licensed agents in 2000, other agents in common use, and numerous combinations of >/=3 drugs, awareness and recognition of adverse effects are increasingly important for clinicians and patients. The common adverse drug reactions encountered with HAART, including new agents and their impact on patient adherence, are reviewed. Current strategies to anticipate and mitigate adverse effects are summarized.

show abstract

“…It is known that patients taking zidovudine (AZT) or stavudine (D4T) leads to an increase in the mean red cell volume (MCV) 33,34 . The reasons for this are unclear but are thought to relate to their effects on DNA synthesis resulting in delayed nuclear maturation and macrocytosis, similar to what occurs with vitamin B12 or folate de® ciency.…”

Section: Introductionmentioning

confidence: 99%

Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence

et al. 2002

View full text Add to dashboard Cite

To assess whether changes in mean cell volume (MCV) could be used as a surrogate marker of adherence, the percentage rise from the baseline MCV (%MCV rise) was compared to an independent marker of adherence, the number of days of medications dispensed in a 24-week period. Nucleoside analogues were found to differ in the extent to which they affect the MCV. The correlation between zidovudine (AZT) (30 subjects) and stavudine (D4T) (41 subjects) with adherence based on prescriptions was 0.82 (P<0.05) and 0.55 respectively (P<0.05). When adherence was categorized into 10% intervals, there was a progressive rise in the average MCV with increasing adherence that plateaus at 70% adherence. Plotting %MCV rise on time charts appears to detect those subjects with adherence of less than 70%. In conclusion, changes in MCV for HIV-positive patients taking either AZT or D4T may be a useful surrogate marker for adherence to anti-retroviral medications.

show abstract

Stavudine induced macrocytosis.

Cited by 6 publications

References 1 publication

Value of Patient Self‐Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response

Value of Patient Self‐Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response

Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence

Contact Info

Product

Resources

About